Axplora, Farmabios, Pharmazell and Novasep DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News

Martin Meeson appointed as CEO of Axplora

10 Apr 2024

// PRESS RELEASE

Axplora plans €8m investment at French facility

30 Jan 2024

// PRESS RELEASE

Axplora announces the appointment of its Scientific Advisory Board

13 Nov 2023

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

CPhI Worldwide, Milan

Booth #2A18

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

1 INTERVIEW #SpeakPharma, 1 VLOG #PharmaReel, 16 CORPORATE CONTENT #SupplierSpotlight, 1 DATA COMPILATION #PharmaFlow, 120 NEWS #PharmaBuzz

media
1 INTERVIEW #SpeakPharma
1 VLOG #PharmaReel
16 CORPORATE CONTENT #SupplierSpotlight
1 DATA COMPILATION #PharmaFlow
120 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

125 All APIs, 62 USDMF, 42 CEP/COS, 24 JDMF, 19 EU WC, 26 KDMF, 104 NDC API, 95 Listed APIs

125 All APIs
62 USDMF
42 CEP/COS
24 JDMF
19 EU WC
26 KDMF
104 NDC API
95 Listed APIs

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

INTERMEDIATES

1 ALL Intermediates

1 ALL Intermediates

KEY PRODUCTS

Acetylcysteine, Balsalazide Disodium, Beclomethasone Dipropionate, Carbocisteine, Carbocysteine Lysine, Lysine, Lysine Acetate, Lysine Hydrochloride, Mesalazine, Methylene Blue, Olaparib, Propafenone Hydrochloride, Triamcinolone, Triamcinolone Acetonide, Triamcinolone Diacetate, Triamcinolone Hexacetonide, Ursodeoxycholic Acid, Zavegepant HCl

Acetylcysteine
Balsalazide Disodium
Beclomethasone Dipropionate
Carbocisteine
Carbocysteine Lysine
Lysine
Lysine Acetate
Lysine Hydrochloride
Mesalazine
Methylene Blue
Olaparib
Propafenone Hydrochloride
Triamcinolone
Triamcinolone Acetonide
Triamcinolone Diacetate
Triamcinolone Hexacetonide
Ursodeoxycholic Acid
Zavegepant HCl

SERVICES

API Manufacturing, API & Drug Product Development

KEY SERVICES

Complex API Development Services, CDMO for Small Molecule APIs, API Custom Synthesis, Hazardous Chemistry, Flow Chemistry, Industrial Chromatography, Contract Development & Manufacturing for ADCs

Complex API Development Services
CDMO for Small Molecule APIs
API Custom Synthesis
Hazardous Chemistry
Flow Chemistry
Industrial Chromatography
Contract Development & Manufacturing for ADCs

INSPECTIONS & REGISTRATIONS

30 FDA, 44 EDQM, 1 WHO-GMP, 5 GDUFA

inspections
30 FDA
44 EDQM
1 WHO-GMP
5 GDUFA

Axplora- The partner of choice for complex APIs.

About

Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

CPhI Worldwide, MilanCPhI Worldwide, Milan

Industry Trade Show

Booth #2A18

08-10 October, 2024

Fiera Milano, Italy
World ADC- San DiegoWorld ADC- San Diego

Industry Trade Show

Attending

04-07 November, 2024

San Diego, CA
CPhI India 2024CPhI India 2024

Industry Trade Show

Attending

26-28 November, 2024

India Expo Centre, Greater Noida

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Germany

Address

Headquarters, HochstraB-Süd 7, 83064 Raubling

Telephone

axplora@axplora.com

Website

https://www.axplora.com

https://www.linkedin.com/company/axplora

Digital content

Explore the latest content creation from this company

INTERVIEW #SpeakPharma

"Axplora’s leading position in ADCs and how it is well-placed to serve the burgeoning GLP1 market"

This week, SpeakPharma interviews Martin Meeson, CEO of Axplora, a leading and reliable API manufacturing partner to some of the world’s biggest pharma and biotech companies. Meeson discusses Axplora’s expansion in the antibody-drug-conjugate (ADC) space and how it is well-placed to serve the exciting market for glucagon-like peptide 1 (GLP-1) drugs with its industrial footprint and purification technologies across several sites. 🔑 HIGHLIGHTS// API manufacturing partner to some of the world’s biggest pharma and biotech companies As a leader in the pharmaceutical industry, what inspired you to join Axplora? And, what do you consider the most rewarding aspect of your role as its CEO? When you look at Axplora as the custodian of strong brands like Farmabios, Pharmazell and Novasep you cannot help but be intrigued by what such breadth of offering and depth of technical expertise can achieve. Well, I was certainly intrigued! As a leader in the pharma space, the opportunity to guide an organization with several decades of experience is inspiring for me. For example, our site in Leverkusen was founded over 150 years ago by Alfred Nobel. With every meeting and site visit, I get increasingly impressed by the capabilities of the people that I meet. Now, it is my job to make sure that these capabilities are given the best opportunity to serve. In this sector, we have the privilege of working with our partners to supply and develop medicines that have such a positive impact on people’s lives. This for me is the most rewarding thing that we do. Sometimes the work that we do can seem a little far away from the patient. I always take time to remind myself, my staff, and hopefully also your readers of what we are doing and how our work impacts others. 🔑 HIGHLIGHTS// strong brands like Farmabios, Pharmazell and Novasep / positive impact on people’s lives How have recent industry developments influenced both API manufacturing and CDMO sectors, and what specific strategies has Axplora implemented to adapt to these changing market dynamics while maintaining its commitment to quality and innovation? As a CDMO, when you partner with us, there is always a focus on reliable supply, and we are still haunted by the challenges all of us faced during the pandemic. At Axplora, we have implemented numerous initiatives to increase the robustness of supply, particularly in looking at advances in sourcing and horizontal integration both within and across our network. At the same time, we have a strong focus on the impact that we are having on the planet and Axplora’s work in this area is tremendous — from increasing the amount and efficacy of waste management, notably the current programs around solvent recovery and recycling, to implementing more environment-friendly technologies such as electrochemistry. I am particularly excited by the cutting-edge work on moving to completely new processes that are water-based rather than solvent-based, creating a step change in impact for us and our partners. In addition, as a CDMO you have to constantly look at where your services fit within evolving markets. Axplora’s expansion in the ADC sector is an excellent example of tracking and investing in emerging technologies. Of note also is the current demand for GLP-1 medicines, and Axplora is well-placed to serve this exciting market with our industrial footprint in small molecules and purification technologies across several sites in our network. 🔑 HIGHLIGHTS// increase the robustness of supply / efficient waste management programs and environment-friendly technologies Can you discuss any recent advancement or breakthrough in API manufacturing or CDMO services at Axplora that have contributed to the company’s success? Our investment in ADC expansion is a key strength. Our Novasep business has some of the world’s leading capabilities in API manufacturing and purification. It is known worldwide for these capabilities. With increasing demand for GLP-1 drugs and the amazing impact they are having on patients globally, we are ready to support this growth across our extensive network. The race to oral dose medicines in this space is particularly exciting, and Axplora is looking forward to treating the vast patient population in diabetes and obesity. 🔑 HIGHLIGHTS// expansion in the ADC sector / treat the vast patient population in diabetes and obesity Looking ahead, what are some of the trends or developments you foresee in API manufacturing and CDMO services, and how is Axplora preparing to stay ahead of the curve in this ever-evolving pharmaceutical landscape? Whilst the landscape is evolving rapidly, regulations are not necessarily able to keep pace with the development of new molecules. The pandemic revealed that things can move more quickly. When I look at the challenging new regulation in adjacent spaces like cell therapy, I wonder how that pace can be applied to our sectors. To that end, you have to remain agile and responsive to customer needs. We have to ensure we invest to grow our capacity in the right areas. Our recent investments in Farmabios in Gropello Cairoli (Italy) to support our thriving steroids business and in Pharmazell in Vizag (India) to advance our specialty business are clear indications of how we can do this very successfully. It would be easier if I could point to just one thing that we are doing, but that is not how we win. The only way to stay ahead is by making a myriad of large and small adjustments and evolutions and that is where the Axplora group excels. Finally, one element I should mention is that we are part of a global supply chain. Therefore, our broad network stands ready to supply medicines to multiple geographies. Our investments reflect our worldwide customer base and ambitions. We are here to serve our partners and their patients. 🔑 HIGHLIGHTS// recent investments in Farmabios in Italy and Pharmazell in India / ready to supply medicines to multiple geographies

Impressions: 2604